Global CEO Grouping Lays Out Japan, Wider Priorities Ahead Of G7 Meeting
UHC, Access, Pricing In Spotlight
Executive Summary
The Biopharmaceutical CEO Roundtable has added a chorus of C-suite voices to ongoing calls for Japan reform discussions, while also flagging key global health agenda items for the upcoming G7 meeting in the country.
You may also be interested in...
G20 Meets Fresh Wave Of COVID With ‘Be Prepared’ Motto, Digital Focus
As the COVID-19 graph trends upward in countries like India, preparing for future pandemics is high on the agenda of intergovernmental forum G20. Digital healthcare and governance tools, One Health approach and tackling AMR emerged as focus areas at the recent meeting of its Health Working Group
Japan Eyes Cutting Reimbursement For COVID-19 Drugs
Japan will end full reimbursement coverage for COVID-19 therapeutic drugs from October, after downgrading the status of the virus to the same level as seasonal flu in early May. As authorities discuss the possible coverage reduction, a larger than usual price cut may also be applied to Shionogi's oral COVID antiviral Xocova.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.